Takeda Pharmaceutical (TKPHF) Receivables Refunds (2018 - 2025)
Historic Receivables Refunds for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to $139.4 million.
- Takeda Pharmaceutical's Receivables Refunds fell 1037.41% to $139.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $139.4 million, marking a year-over-year decrease of 1037.41%. This contributed to the annual value of $103.7 million for FY2025, which is 4881.99% down from last year.
- Per Takeda Pharmaceutical's latest filing, its Receivables Refunds stood at $139.4 million for Q4 2025, which was down 1037.41% from $90.1 million recorded in Q3 2025.
- In the past 5 years, Takeda Pharmaceutical's Receivables Refunds ranged from a high of $513.6 million in Q4 2022 and a low of $90.1 million during Q3 2025
- Moreover, its 5-year median value for Receivables Refunds was $232.2 million (2023), whereas its average is $226.8 million.
- As far as peak fluctuations go, Takeda Pharmaceutical's Receivables Refunds skyrocketed by 16624.67% in 2021, and later plummeted by 6463.13% in 2023.
- Quarter analysis of 5 years shows Takeda Pharmaceutical's Receivables Refunds stood at $357.2 million in 2021, then surged by 43.78% to $513.6 million in 2022, then plummeted by 64.63% to $181.6 million in 2023, then dropped by 14.37% to $155.5 million in 2024, then dropped by 10.37% to $139.4 million in 2025.
- Its last three reported values are $139.4 million in Q4 2025, $90.1 million for Q3 2025, and $96.1 million during Q2 2025.